Evommune is a clinical-stage biotechnology company focused on chronic inflammatory diseases. Its primary pipeline features EVO756 (an oral MRGPRX2 antagonist being evaluated for chronic spontaneous urticaria and migraine prophylaxis) and EVO301 (an IL-18bp fusion protein targeting atopic dermatitis and other immunological disorders).